Advertisement
U.S. markets open in 8 hours 4 minutes

Galectin Therapeutics Inc. (GALT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.6300+0.0300 (+1.15%)
At close: 04:00PM EDT
2.7010 +0.07 (+2.70%)
After hours: 05:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.6000
Open2.6300
Bid2.6400 x 100
Ask2.7200 x 100
Day's Range2.6100 - 2.7050
52 Week Range1.5600 - 4.2700
Volume200,450
Avg. Volume122,261
Market Cap163.791M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-0.7800
Earnings DateNov 11, 2024 - Nov 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

    NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, C

  • GlobeNewswire

    Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

    NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of